ArticleFrontiers in pharmacology2026
Formononetin: a promising therapeutic agent targeting the gut-lung axis in acute lung injury.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lung injury (ALI) is a common acute inflammatory lung disease in critical clinical conditions, with a complex pathogenesis and limited available treatment options. Although the gut-lung axis has been identified as an emerging field of host-related microbiota in various chronic lung diseases, it remains unclear whether gut microbiota is associated with the development and progression of ALI. Objective: This study aims to investigate the therapeutic effects of formononetin on ALI mice and elucidate how formononetin ameliorates ALI by regulating the gut-lung axis. Methods: Pathological changes in lung and intestinal tissues of LPS-induced ALI mice were first examined using histopathological detection. Reverse transcription quantitative real-time PCR (RT-qPCR) and Western blot (WB) were employed to assess lung/intestinal inflammation and intestinal barrier integrity. 16S rRNA sequencing was used to evaluate the intestinal microbial microenvironment, and metabolomics was applied to detect changes in serum metabolites. Results: Formononetin effectively ameliorated lung injury in ALI mice, reduced the expression of lung/intestinal inflammatory factors, and protected the integrity of the lung-intestinal barrier in ALI mice. Gut microbiota analysis revealed that the anti-ALI effect of formononetin may be associated with Parabacteroides. Metabolite pathway enrichment involved bile acid metabolism and ABC transporters. Conclusion: Formononetin reverses lung injury and repairs the gut-lung barrier in ALI mice. These effects are accompanied by changes in Parabacteroides abundance, as well as alterations in ABC transporters and bile secretion. This study provides new insights and potential applications for the clinical intervention of ALI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.